Back to English top Investment Strategy

Sundrug (9989) Stable performance but limited growth acceleration

2026-05-02

SYSTEM NOTICE

This content has been translated automatically by AI. Translation accuracy, nuances, and the author's original intent may not be fully reflected. In the event of any discrepancy, the original Japanese version shall prevail.

View Original Japanese

[Summary]

Although Sundrug maintains an increasing trend of sales and profits, the growth rate is moderate and the evaluation is neutral. Recovery in same-store sales and inbound demand contributed. On the other hand, rising labor costs and purchasing costs suppressed profit growth. Although it is highly stable as a defensive stock, the stock price is already factored in to a certain extent. This is a phase in which it is more important to confirm the accumulation of business results than to look for large increases in the short term.

Retail Drugstore Defensive Financial analysis Japanese stocks

Overview

Sales: Increase in sales *Operating income: Increase
Final profit: increase *YoY: Moderate growth
One word: Stable growth, but weak sense of acceleration

Financial Highlights (Simple Table)

Indicators	Contents
Sales	+several percent growth
Operating income	Slight increase
Final profit	Increase in profit
Factor 1	Existing store recovery
Factor 2	Inbound demand

What happened (most important)

Quantity Existing store customer numbers are on a recovery trend Inbound demand boosts

→ Structure + external factors (semi-structure)

Price Price increase effect is limited Low price orientation continues

→ Structure

Cost Rising labor costs Increase in logistics costs

→ Structural cost increase

Exchange Purchasing costs increase due to weak yen

→ External factors

Latest materials (3 months)

Financial results announcement: solid performance but no surprises
Market reaction: limited
Inbound recovery continues
Competitive environment: Price competition among drugstores

→ Stock prices tend to fluctuate in a range

Business structure

Source of revenue: Sales of pharmaceuticals and daily necessities
Profit margin: Medium (stable for retail)
Strengths: Suburban/low-cost operation
Weaknesses: Price competition/difficulty in differentiation

Implications for stock prices

*Positive: Defensiveness

Negative: Slowdown in growth
Incorporated: Stable growth is already reflected.
Gap: Limited room to accelerate growth

Short term (6 months)

Inbound trends
Existing store sales
Growth in personnel costs

→ Small fluctuations in business results affect stock prices

Mid-term (1 year)

Growth: low to medium *Profit structure: Stable but with pressure factors
Valuation: Defensive evaluation

Scenario analysis

Bullish: 25% Inbound expansion + cost absorption → stock price rise

Neutral: 50% Continued stable growth → flat trend

Bearish: 25% Increased costs + intensified competition → downward pressure

Risk (simple table)

Risk	Contents
Personnel costs	Profit pressure
Foreign exchange	Purchase cost increase
Competition	Declining profit margin

Summary

Conclusion: Neutral
Stable growth continues
However, it is difficult to see growth acceleration *Next focus: Existing stores + cost trends